Department of Epidemiolog, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Department of Epidemiology, University of Maryland.
Ophthalmol Glaucoma. 2019 Nov-Dec;2(6):374-382. doi: 10.1016/j.ogla.2019.07.005. Epub 2019 Jul 31.
To explore patients' perspectives and experiences living with glaucoma and identify important benefits and risks that patients consider before electing for new glaucoma treatments, such as minimally invasive glaucoma surgical (MIGS) devices.
Semi-structured, in-person qualitative interviews with patients seen at the Johns Hopkins Wilmer Eye Institute.
Adults older than 21 years of age who were suspected or diagnosed with ocular hypertension or mild to moderate primary open-angle glaucoma (POAG) (and thus eligible for treatment with a MIGS procedure) presenting to a glaucoma clinic in Baltimore, Maryland, between May and December 2016.
We conducted in-person interviews with patients recently diagnosed with ocular hypertension or POAG. We focused on considerations patients take into account when deciding between different treatments. We used the framework approach to code and analyze the qualitative data. Considerations of special interest to us were those that can be translated into outcomes (or endpoints) in clinical trials.
Patients' perspectives concerning outcomes that matter to them when managing ocular hypertension or POAG.
Ten male and fifteen female patients participated in our study. The median participant age was 69 years (range 47 - 82 years). We identified outcomes that patients expressed as important, which we grouped into four thematic categories: (1) limitations in performing specific vision-dependent activities of daily living; (2) problems with general visual function or perceptions; (3) treatment burden, including ocular adverse events; and (4) intraocular pressure (IOP). All 25 participants expressed some concerns with their ability to perform vision-dependent activities, such as reading and driving. Most (23/25) participants had an opinion about IOP, and among those currently taking ocular hypotensive eye drops, all recognized the relationship between eye drops and IOP.
We have identified outcomes that matter to patients who are deciding between different treatments for ocular hypertension and POAG, such as the ability to drive or maintain mobility outside the home. These outcomes will be important in future evaluations of new treatments for glaucoma.
探讨患者患有青光眼的观点和体验，并确定患者在选择新的青光眼治疗方法（如微创青光眼手术（MIGS）装置）之前考虑的重要益处和风险。
在马里兰州巴尔的摩的威尔默眼科研究所就诊的疑似或诊断为高眼压或轻度至中度原发性开角型青光眼（POAG）的患者中进行半结构式面对面定性访谈。
21 岁以上的成年人，患有疑似或诊断为高眼压或 POAG（因此有资格接受 MIGS 手术治疗），于 2016 年 5 月至 12 月在马里兰州巴尔的摩的威尔默眼科研究所的青光眼诊所就诊。
我们对最近被诊断为高眼压或 POAG 的患者进行了面对面访谈。我们专注于患者在决定不同治疗方法时考虑的因素。我们使用框架方法对定性数据进行编码和分析。我们特别关注那些可以转化为临床试验结果（或终点）的考虑因素。
患者在管理高眼压或 POAG 时对重要结果的看法。
10 名男性和 15 名女性患者参加了我们的研究。中位参与者年龄为 69 岁（范围 47-82 岁）。我们确定了患者认为重要的结果，将其分为四个主题类别：（1）进行特定与视力相关的日常生活活动的能力受限；（2）一般视觉功能或感知问题；（3）治疗负担，包括眼部不良反应；（4）眼内压（IOP）。所有 25 名参与者都对他们进行与视力相关的活动的能力表示出一些担忧，例如阅读和驾驶。大多数（23/25）参与者对 IOP 有意见，而在目前使用降眼压眼药水的患者中，所有人都认识到眼药水与 IOP 的关系。
我们已经确定了对正在考虑不同治疗方法治疗高眼压和 POAG 的患者重要的结果，例如驾驶或保持家庭以外活动的能力。这些结果将对新的青光眼治疗方法的未来评估非常重要。
